Pharma’s Almanac’s Q2 2024 roundtable ‘What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?’ features a response from Nigel Theobald, CEO, N4 Pharma.Contributing to the discussion, Nigel highlights the need for investment into new non-lipid delivery systems like Nuvec® in [...]

Our latest article explores the challenges with targeting the gastrointestinal (GI) tract and outlines the current strategies aiming to unlock the potential of oral delivery for siRNA drugs targeted against GI diseases and cancers. We discuss why silica nanoparticles, such as Nuvec®, are one of the most promising siRNA [...]

Shares Magazine shines a spotlight on N4 Pharma (N4P:AIM), revolutionising biotech with advanced delivery systems for nucleic acids in oncology, gene therapy, and vaccines. Our patented mesoporous silica nanoparticles and newly acquired lipid-peptide delivery platform ensure precise, targeted treatment. We aim to become a leading supplier to major pharma [...]

In an interview with World Pharma Today, Nigel Theobald, CEO N4 Pharma, answers questions about the company’s latest news and future plans. Key highlights from the discussion include: Acquisition: our recent acquisition of Nanogenics Limited and how it enhances our product offerings in gene therapy. Collaborative partnerships: our partnerships [...]

In our latest article, we look at how the dual delivery of siRNA – via delivery systems such as Nuvec® – holds the potential to pave the way for a new era of improved efficiency in cancer treatment. Nuvec® has the potential to offer a solution that reduces the [...]

In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of [...]